false
--12-31
0001506983
0001506983
2024-06-14
2024-06-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 14, 2024
GLUCOTRACK,
INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41141 |
|
98-0668934 |
(State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
301
Rte 17 North, Ste. 800, Rutherford, NJ |
|
07070 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (201) 842-7715
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
GCTK |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors
as an independent board member. Mr. Balo joined DexCom International, Ltd. as part of the original
executive team in 2002 and played a critical role in shaping the company’s future. During his tenure, he was responsible for numerous
glucose monitoring regulatory submissions and clinical trials worldwide and coordinated quality activities across multiple manufacturing
facilities. From February 2022 until his retirement onMarch 24, 2024, Mr. Balo served as Executive Vice
President of Clinical, Global Access, and Medical Affairs. Prior to joining Dexcom, Mr. Balo held several leadership positions at St.
Jude Medical, including Corporate Vice President of Regulatory, Clinical, and Quality, and also served in executive roles at Baxter,
Pacesetter and Endocardial Solutions.
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On
June 14, 2024, the Board of Directors of the Company voted to amend the Company’s bylaws to reduce the quorum requirement for a
meeting of shareholders from the holders of record of
a majority of the shares then issued and outstanding and entitled to vote at the meeting to one-third. The foregoing description of the
First Amendment to Bylaws does not comport to be complete and is subject to, and is qualified in its entirety by reference to, the full
text of the amendment which is attached as Exhibit 3.1 to this Current Report on Form 8-K, and is incorporated herein by reference.
Item
7.01 Regulation FD Disclosure
On
June 20, 2024, the Company issued a press release (the “Press Release”) regarding Mr. Balo’s appointment to
the Board of Directors. The Press Release is furnished as Exhibit 99.1 and incorporated into this Item 7.01 by reference.
The
information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference into any filing with the Securities and Exchange
Commission, except as expressly set forth by specific reference in such a filing.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
Forward-Looking
Statements
This
Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by words such as “projects,” “may,” “will,”
“could,” “would,” “should,” “believes,” “expects,” “anticipates,”
“estimates,” “intends,” “plans,” “potential,” “promise” or similar references
to future periods. Examples of forward-looking statements in this Current Report on Form 8-K include, without limitation, statements
regarding the Company’s intent or ability to regain compliance with the Minimum Bid Price Requirement and the Minimum Stockholders’
Equity Requirement, the outcome of the Nasdaq hearing and appeal process, and the anticipated actions
by the Nasdaq staff and the Company’s responses and their anticipated outcome, and the ability for the common stock to remain listed
on Nasdaq. Any forward-looking statements in this Current Report on Form 8-K are based on management’s
current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks
and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained
in or implied by the forward-looking statements, see the section entitled “Risk Factors” in the Company’s Annual Report
on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 28, 2024, as well as discussions of potential risks, uncertainties
and other important factors in any subsequent Company filings with the Securities and Exchange Commission. All information in this Current
Report on Form 8-K is as of the date of the filing; the Company undertakes no duty to update this information unless required by law.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
June 20, 2024 |
|
|
|
|
|
|
GLUCOTRACK,
INC. |
|
|
|
|
By: |
/s/
Paul Goode |
|
Name: |
Paul
Goode |
|
Title: |
Chief
Executive Officer |
Exhibit
3.01
FIRST
AMENDMENT TO BYLAWS
OF
GLUCOTRACK,
INC.
In
accordance with resolutions adopted by the Board of Directors of Glucotrack, Inc. (the “Corporation”), a Delaware
corporation, the Bylaws of the Corporation (the “Bylaws”), adopted July 15, 2020, are hereby amended as set forth
in this First Amendment to Bylaws (“First Amendment”), effective June 14, 2024. Capitalized Terms used and not otherwise
defined in this First Amendment shall have the meaning set forth in the Bylaws.
AMENDMENT
1.
Article II, Section 2.07 of the Bylaws is deleted in its entirety and replaced with the following:
Section
2.07. QUORUM. At any meeting of stockholders of the Corporation, the presence, in person or by proxy, of the holders of record
of one-third of the shares then issued and outstanding and entitled to vote at the meeting shall constitute a quorum for the transaction
of business; provided, however, that this Section 2.07 shall not affect any different requirement which may exist
under statute, pursuant to the rights of any authorized class or series of stock, or under the Certificate of Incorporation of the Corporation,
as amended or restated from time to time (the “Certificate of Incorporation”), for the vote necessary for the adoption
of any measure governed thereby. The stockholders present at a duly called and held meeting at which a quorum is present may continue
to do business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum, if any action taken
(other than adjournment) is approved by at least a majority of the shares required to constitute a quorum.
In
the absence of a quorum, the stockholders present in person or by proxy, by majority vote and without further notice, may adjourn the
meeting from time to time until a quorum is attained, but in the absence of a quorum, no other business may be transacted at that meeting,
except as provided in this section. At any reconvened meeting following such adjournment at which a quorum is present, any business may
be transacted which might have been transacted at the meeting as originally noticed.
2.
Except as amended hereby, all terms and provisions of the Bylaws shall remain unchanged and in full force and effect.
IN
WITNESS WHEREOF, the undersigned, on behalf of the Corporation, has executed this First Amendment to the Bylaws as of 14th day of June,
2024.
|
By:
|
/s/
Paul Goode |
|
Name:
|
Paul
Goode |
|
Title:
|
Chief
Executive Officer |
Exhibit
99.1
GLUCOTRACK
ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS
Diabetes
industry veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with
diabetes
Rutherford,
NJ, June 20, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”),
a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes,
today announced that it has appointed Andy Balo to its Board of Directors, effective immediately.
Mr.
Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. In 2002 he joined Dexcom
as part of the original executive team where he remained for the next 22 years playing a critical role in shaping the company’s future. During his tenure,
he was responsible for numerous glucose monitoring regulatory submissions and clinical trials worldwide and coordinated quality activities
across multiple manufacturing facilities. In March 2024, Mr. Balo retired from Dexcom as Executive Vice President of Clinical, Global
Access, and Medical Affairs. Prior to joining Dexcom, Mr. Balo held several leadership positions at St. Jude Medical, including Corporate
Vice President of Regulatory, Clinical, and Quality, and also served in executive roles at Baxter, Pacesetter and Endocardial Solutions.
Mr.
Balo is widely regarded as an industry expert in regulatory and clinical strategies. He has served on several FDA panels as an industry
representative, spanning cardiovascular, neurological, and gastrointestinal technologies. He has been instrumental in bringing several
breakthrough medical devices to market, including continuous glucose monitors, tissue-based and mechanical heart valves, 3-D electrophysiology
mapping devices, pacemakers, and has obtained approval for over 100 PMAs, PMA supplements and 510ks.
Mr.
Balo holds a Bachelor of Science degree in microbiology and chemistry from the University of Maryland and completed graduate studies
at UCLA.
“We
are honored to have Andy join our Board of Directors,” said Paul Goode, PhD, CEO of Glucotrack. “He is nationally recognized
as a thought leader in the regulatory and clinical landscape, and his experience in diabetes and cardiovascular technologies will be
invaluable as we move into human clinical studies for our unique technology. Additionally, Andy is an authentic, driven and passionate
leader who will help guide the company through our regulatory, clinical and commercialization milestones.”
“I
am excited to be joining the Board of such an innovative and nimble medical technology company,” said Mr. Balo. “Glucotrack’s
continuous blood glucose monitor (CBGM) is a very compelling product that bridges diabetes and cardiovascular technology, leveraging
established techniques and tools to create a truly differentiated glucose monitoring product. I look forward to working with the Board
and the leadership team to bring this groundbreaking technology to people living with diabetes every day.”
For
more information about Glucotrack, visit glucotrack.com.
Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
#
# #
About Glucotrack,
Inc.
Glucotrack,
Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The
Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s
CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body
wearable component and with minimal calibration. For
more information, please visit http://www.glucotrack.com.
Forward-Looking
Statements
This
news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements
contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting
the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will”
are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well
as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on
which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as
a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this
press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack
will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business
or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such
results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s
results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through
public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing)
of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the
conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire
and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s
filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year
ended December 31, 2023 as filed with the SEC on March 28, 2024.
Contacts:
Investor
Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
v3.24.1.1.u2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 8 2024 まで 9 2024
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 9 2023 まで 9 2024